Latisse Review and Coupons

Last year, AstraZeneca and Targacept based on North Carolina announced that they did not have in two clinical trials of final phase of a drug deal with major depressive disorder.  I hope remains however in the results of two other yet to be completed.  Yesterday, these negative results led to the abandonment of the program completely.

AstraZeneca said that the drug did not work as expected in a trial of eight weeks, compared with placebo. The announcement was not a shock to all those who have followed the news earlier but is certainly a coup for both companies.

FierceBiotech was especially: well, fierce – calling the program “a full bust” and Targacept describes as “Crouch as leaders met behind a substantial wall of cash, while being prepared for inevitable judgment in a defensive”.

With M $225 species but little influence, CEO of Targacept has announced that the company might launch his plans next month.  The company has other products in the pipeline of early stage focused on asthma, Alzheimer’s disease, diabetes, schizophrenia and ADHD.  GSK has finalized its Targacept Association year last in a reduction of its work in neuroscience.  One might think that the Targacept to focus their efforts and fate of his investment of cash.

As for Astrazeneca, continue their afflictions.  The Big Pharma company essentially left the category of neuroscience and was reprimanded by analysts and investors to not strengthen its portfolio of final phase.  2012 is intense in the AZ Cliff patent as the company will lose 4 1 300 million in revenues when Seroquel patent expires in December, in the wake of us $2 billion in lost revenue for makers of generic drugs in 2011.  In General, dólares-valor de 27 million in sales of blockbuster will be to generic competition in the United States, according to Fitch Ratings.

Associated Press

Cancel response

Leave a comment

Name